Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
Clinical trial NCT07297563 · RECRUITING
Trial details
- NCT number
- NCT07297563
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-20
- Primary completion
- 2027-11-01
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.